WO2006089023A3 - Pharmaceutical compositions for treating or preventing bone conditions - Google Patents

Pharmaceutical compositions for treating or preventing bone conditions Download PDF

Info

Publication number
WO2006089023A3
WO2006089023A3 PCT/US2006/005473 US2006005473W WO2006089023A3 WO 2006089023 A3 WO2006089023 A3 WO 2006089023A3 US 2006005473 W US2006005473 W US 2006005473W WO 2006089023 A3 WO2006089023 A3 WO 2006089023A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
pharmaceutical compositions
preventing bone
bone conditions
preventing
Prior art date
Application number
PCT/US2006/005473
Other languages
French (fr)
Other versions
WO2006089023A2 (en
Inventor
Chia Soo
Kang Ting
Shunichi Kuroda
Ben Wu
Original Assignee
Univ California
Chia Soo
Kang Ting
Shunichi Kuroda
Ben Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2007556289A priority Critical patent/JP2008530227A/en
Priority to US11/884,525 priority patent/US7833968B2/en
Priority to CA002597605A priority patent/CA2597605A1/en
Priority to EP06735230A priority patent/EP1851237A4/en
Application filed by Univ California, Chia Soo, Kang Ting, Shunichi Kuroda, Ben Wu filed Critical Univ California
Publication of WO2006089023A2 publication Critical patent/WO2006089023A2/en
Priority to US11/594,510 priority patent/US7687462B2/en
Priority to US11/601,529 priority patent/US7691607B2/en
Publication of WO2006089023A3 publication Critical patent/WO2006089023A3/en
Priority to US12/700,644 priority patent/US8044026B2/en
Priority to US12/700,630 priority patent/US8053412B2/en
Priority to US12/897,397 priority patent/US9511115B2/en
Priority to US13/253,859 priority patent/US20120077742A1/en
Priority to US15/367,097 priority patent/US10335458B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Abstract

Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.
PCT/US2006/005473 1999-10-05 2006-02-16 Pharmaceutical compositions for treating or preventing bone conditions WO2006089023A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2007556289A JP2008530227A (en) 2005-02-16 2006-02-16 Pharmaceutical composition for treating or preventing bone conditions
US11/884,525 US7833968B2 (en) 2005-02-16 2006-02-16 Pharmaceutical compositions for treating or preventing bone conditions
CA002597605A CA2597605A1 (en) 2005-02-16 2006-02-16 Pharmaceutical compositions for treating or preventing bone conditions
EP06735230A EP1851237A4 (en) 2005-02-16 2006-02-16 Pharmaceutical compositions for treating or preventing bone conditions
US11/594,510 US7687462B2 (en) 1999-10-05 2006-11-07 Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
US11/601,529 US7691607B2 (en) 2004-02-09 2006-11-17 Expression system of NELL peptide
US12/700,630 US8053412B2 (en) 2004-02-09 2010-02-04 NELL-1 peptides
US12/700,644 US8044026B2 (en) 1999-10-05 2010-02-04 Composition for promoting cartilage formation or repair comprising a NELL gene product and method of treating cartilage-related conditions using such composition
US12/897,397 US9511115B2 (en) 2005-02-16 2010-10-04 Pharmaceutical compositions for treating or preventing bone conditions
US13/253,859 US20120077742A1 (en) 2004-02-09 2011-10-05 Expression System Of NELL Peptide
US15/367,097 US10335458B2 (en) 2005-02-16 2016-12-01 Pharmaceutical compositions for treating or preventing bone conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65372205P 2005-02-16 2005-02-16
US60/653,722 2005-02-16

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/003808 A-371-Of-International WO2004072100A2 (en) 1999-10-05 2004-02-09 Nell peptide expression systems and bone formation activity of nell peptide
US11/392,294 Continuation-In-Part US7776361B2 (en) 1999-10-05 2006-03-28 NELL-1 enhanced bone mineralization

Related Child Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2004/003808 Continuation-In-Part WO2004072100A2 (en) 1999-10-05 2004-02-09 Nell peptide expression systems and bone formation activity of nell peptide
US10/544,553 Continuation-In-Part US7544486B2 (en) 1999-10-05 2004-02-09 Nell peptide expression systems and bone formation activity of nell peptide
US11/884,525 A-371-Of-International US7833968B2 (en) 2005-02-16 2006-02-16 Pharmaceutical compositions for treating or preventing bone conditions
US11/544,553 Continuation-In-Part US7515863B2 (en) 2005-10-21 2006-10-10 Cleaning unit and image forming apparatus using the same
US11/594,510 Continuation-In-Part US7687462B2 (en) 1999-10-05 2006-11-07 Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
US11/601,529 Continuation-In-Part US7691607B2 (en) 2004-02-09 2006-11-17 Expression system of NELL peptide
US12/897,397 Division US9511115B2 (en) 2005-02-16 2010-10-04 Pharmaceutical compositions for treating or preventing bone conditions

Publications (2)

Publication Number Publication Date
WO2006089023A2 WO2006089023A2 (en) 2006-08-24
WO2006089023A3 true WO2006089023A3 (en) 2007-02-01

Family

ID=36917042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/005473 WO2006089023A2 (en) 1999-10-05 2006-02-16 Pharmaceutical compositions for treating or preventing bone conditions

Country Status (7)

Country Link
US (3) US7833968B2 (en)
EP (1) EP1851237A4 (en)
JP (1) JP2008530227A (en)
KR (1) KR20070121669A (en)
CN (1) CN101611051A (en)
CA (1) CA2597605A1 (en)
WO (1) WO2006089023A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687462B2 (en) * 1999-10-05 2010-03-30 The Regents Of The University Of California Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7691607B2 (en) 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
JP2008530227A (en) * 2005-02-16 2008-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Pharmaceutical composition for treating or preventing bone conditions
EP2194782B1 (en) * 2007-09-28 2015-11-04 UT-Battelle, LLC Methods for promoting wound healing and muscle regeneration with the cell signaling protein nell 1
CA2704190A1 (en) * 2007-10-30 2009-05-07 Kang Ting Nell-1 compositions
JP2011016723A (en) * 2007-11-02 2011-01-27 Katayama Kagaku Kogyo Kk Medicine and medical instrument containing osteogenic and chondrogenic protein
JP5320183B2 (en) * 2008-06-26 2013-10-23 国立大学法人 岡山大学 Bone quality inspection method for maxillofacial implant treatment
EP2322604A4 (en) 2008-08-04 2014-01-08 Univ Showa Technique for regulating regeneration of tissue or faulty or abnormal part in organ using nell-1
EP2350286B1 (en) * 2008-10-07 2016-07-20 The Regents of The University of California Recombinant nell protein production
WO2010111421A2 (en) 2009-03-25 2010-09-30 The Regents Of The University Of California Isoform nell-1 peptide
WO2011022071A2 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of California Cardiac compositions
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
KR101029705B1 (en) * 2010-06-30 2011-04-18 (주)엔솔테크 Novel peptide and uses thereof
US8614190B2 (en) 2010-06-30 2013-12-24 Industrial Technology Research Institute Thermal responsive composition for treating bone diseases
EP2606121B1 (en) * 2010-08-19 2016-05-11 The Regents of The University of California Compositions comrpising perivascular stem cells and nell-1 protein
CN102579145B (en) * 2012-02-23 2014-05-14 中国人民解放军第四军医大学 Dental implant and preparation method thereof
RU2511430C2 (en) * 2012-04-19 2014-04-10 Общество С Ограниченной Ответственностью "Парафарм" Diagnostic technique for osteoporosis, method for testing cavitary lesion closure behaviour for assessing effective use of various osteoprotectors
WO2015017500A1 (en) 2013-07-30 2015-02-05 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
ES2704748T3 (en) * 2014-06-13 2019-03-19 Univ Wien Bodenkultur Methods for the diagnosis and treatment of fractures and bone disorders
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US10973953B1 (en) 2016-08-18 2021-04-13 Musculoskeletal Transplant Foundation Methods and compositions for preparing transplant tissue
US10752663B2 (en) 2016-08-29 2020-08-25 NellOne Therapeutics, Inc. Methods and compositions for regenerating tissues
KR101991624B1 (en) * 2018-04-11 2019-06-20 서울대학교산학협력단 Transformant derived from diabetes individual, manufacturing method the smae, and cellular therapeutic agents comprising the same
CN112236440A (en) * 2018-05-28 2021-01-15 江阴贝瑞森制药有限公司 Novel pharmaceutical use
US11364323B2 (en) 2018-09-17 2022-06-21 Rejuvablast LLC Combination grafts for tissue repair or regeneration applications
US11090412B2 (en) 2018-12-21 2021-08-17 Zavation Medical Products Llc Bone repair composition and kit
CN110129429A (en) * 2019-05-22 2019-08-16 昌乐县人民医院 Application of the nucleic acid molecules in the product of preparation diagnosis orthopaedic disease
AU2019204031A1 (en) 2019-05-31 2020-12-17 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
CN112891559B (en) * 2021-02-07 2022-04-15 首都医科大学附属北京口腔医院 Polypeptide co-modified naringin nano liposome for promoting proliferation and osteogenic differentiation of dental pulp stem cells and preparation method and application thereof
CN114836535A (en) * 2022-06-24 2022-08-02 四川大学 Method for developing marker for detecting primary osteoporosis based on LncRNA and miRNA signal regulation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4409332A (en) 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5674725A (en) 1991-07-11 1997-10-07 British Technology Group Limited Implant materials having a phosphatase and an organophosphorus compound for in vivo mineralization of bone
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6083690A (en) 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US6352972B1 (en) 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6200606B1 (en) 1996-01-16 2001-03-13 Depuy Orthopaedics, Inc. Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration
US6005088A (en) 1996-03-19 1999-12-21 Otsuka Pharmaceutical Co., Ltd. Human NPIK gene
US5700774A (en) 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
US6077987A (en) 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US7687462B2 (en) * 1999-10-05 2010-03-30 The Regents Of The University Of California Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
US7544486B2 (en) * 2003-02-07 2009-06-09 The Regents Of The University Of California Nell peptide expression systems and bone formation activity of nell peptide
US7052856B2 (en) * 1999-10-05 2006-05-30 The Regents Of The University Of California NELL-1 enhanced bone mineralization
EP1551978A4 (en) * 2002-09-13 2006-02-01 Univ California Nell-1 enhanced bone mineralization
EP1447413A3 (en) * 2003-02-14 2006-01-04 Research Association for Biotechnology Full-length human cDNA
US20060053503A1 (en) * 2004-07-30 2006-03-09 Ut-Battelle, Llc Cranial and vertebral defects associated with loss-of-function of Nell
JP2008530227A (en) 2005-02-16 2008-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Pharmaceutical composition for treating or preventing bone conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KURODA S. ET AL.: "Biochemical characterization and expression analysis of neural thrombospondin-1-like proteins NELL1 and NELL2", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 265, 1999, pages 79 - 86, XP005100839 *
KURODA S. ET AL.: "Involvement of epidermal growth factor-like domain of NELL proteins in the novel protein-protein interaction with protein kinase C", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 265, 1999, pages 752 - 757, XP003007039 *
See also references of EP1851237A4 *

Also Published As

Publication number Publication date
EP1851237A4 (en) 2009-01-07
US9511115B2 (en) 2016-12-06
US20170165323A1 (en) 2017-06-15
WO2006089023A2 (en) 2006-08-24
US20090053311A1 (en) 2009-02-26
EP1851237A2 (en) 2007-11-07
US10335458B2 (en) 2019-07-02
CA2597605A1 (en) 2006-08-24
US20110300184A1 (en) 2011-12-08
CN101611051A (en) 2009-12-23
KR20070121669A (en) 2007-12-27
US7833968B2 (en) 2010-11-16
JP2008530227A (en) 2008-08-07

Similar Documents

Publication Publication Date Title
WO2006089023A3 (en) Pharmaceutical compositions for treating or preventing bone conditions
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2007092622A3 (en) Compositions and methods for treating bone
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2006086562A3 (en) Phenylazetidinone derivatives
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
HK1152493A1 (en) Composition with strontium and vitamin d for the prophylaxis and/or treatment of cartilage and/or bone conditions
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006073457A8 (en) Bioactive compounds and methods of uses thereof
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2008130989A3 (en) Prosthetic implants
WO2004080391A3 (en) Novel antibacterial agents
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2006128143A3 (en) Hydantoin compounds
ZA200706662B (en) Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith
WO2007064304A8 (en) Biocompatible composition and uses thereof
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
CA2659376C (en) 2,4-diaminoquinazolines for spinal muscular atrophy
EP1944027A4 (en) Pharmaceutical composition for treatment or prevention of nephritis and method for producing same
IL186672A0 (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
WO2006055663A3 (en) The use of novel antibacterial compounds
WO2007002881A3 (en) Compositions and methods of use of derivatized flavanols
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680012707.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11594510

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11594510

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2597605

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11884525

Country of ref document: US

Ref document number: 2007556289

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077020929

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006735230

Country of ref document: EP